July 1, 2018 (Vol. 38, No. 13)

Sartorius Stedim Biotech

The new mini bioreactor vessel for the ambr® 250 high throughput (HT) is designed for optimal growth of adherent cells on microcarriers to enable rapid, scalable, cell culture process development of vaccines. It has a working volume of 100–250 mL and features a single Elephant Ear impeller. This impeller type generates optimum mixing and suspension of microcarriers, allowing adherent cells to grow over the entire microcarrier surface. Utilizing this bioreactor on the ambr 250 HT system will allow rapid scale-up of optimized adherent cell culture processes for the BIOSTAT® STR range of pilot and manufacturing scale stirred bioreactors. Simple to set up and use, this new single-use mini bioreactor minimizes set-up and turnaround time. With up to 24 bioreactors per ambr 250 HT system, the technology is ideal for Design of Experiments (DoE) studies to optimize process development for vaccine manufacturing using a Quality by Design (QbD) approach.

Previous articleAlzheimer’s Drugs Targeting Tau May Actually Exacerbate Disease
Next articleTop 10 M&A Deals of January–June 2018